Select a State

Global health R&D delivers for Nebraska

US government investment in global health R&D has delivered

$7.7 million
to Nebraska research institutions
100+ new jobs
for Nebraska

Neglected diseases in Nebraska

Chikungunya cases
8
Dengue cases
22
HIV diagnoses
806
Malaria cases
53
Tuberculosis cases
257
West Nile cases
891
Zika cases
14

Nebraska's top USG-funded global health R&D institutions

University of Nebraska Medical Center
$3.0 million
University of Nebraska Lincoln
$3.0 million
Creighton University
$1.7 million

Nebraska industry in global health R&D

Celerium
Location(s):
Lincoln

Nebraska's top areas of global health R&D by USG funding

44.5%
HIV/AIDS
4.9%
Malaria
5.5%
Tuberculosis
10.9%
Diarrheal diseases
21.4%
Salmonella infections
12.8%
Neglected tropical diseases
Helminths

Global health R&D at work in Nebraska

University of Nebraska Medical Center researchers have used a process called LASER ART (long-acting slow effective release antiretroviral therapy) to extend the action of HIV drugs. By combining LASER ART—a type of injectable drug with an altered chemical structure—with another pharmaceutical agent with no antiviral effect, the scientists showed that the drug composite could reach body tissue conventional drugs cannot. It insulates drug crystals within cells, protecting them from degradation and allowing for the slow release of active ingredients. This breakthrough has the potential to revolutionize HIV therapy. With LASER ART, drug regimens could be transformed from daily burdens to monthly doses, greatly improving patients’ quality of life.

Footnotes